Alemtuzumab

Alemtuzumab is a humanized monoclonal antibody targeting CD52, used to treat chronic lymphocytic leukemia and multiple sclerosis by depleting circulating lymphocytes. It is grouped under the following drug class(es): Monoclonal antibodies. Its therapeutic use is listed as multiple sclerosis agents. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include LDP-03, Monoclonal Antibody Campath-1H and MabCampath. Its PubChem SID is 481101485.

CAS No 216503-57-0
Molecular Formula N/A
Synonyms N/A

Frequently Asked Questions